Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Trending weight loss drugs such as Ozempic and Wegovy may be highly effective at tackling obesity, but are they also carrying ...

This week in Ozempic news: No more compounded GLP-1s, weight-loss pills are coming, and WeightWatchers is filing for ...

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Many people experience a serious return of appetite, cravings and weight after coming off Ozempic, and having read far too ...

A federal judge rejected a bid by compounding pharmacies to continue selling versions of weight-loss drug Wegovy and diabetes ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final ...

Weight loss drugs can cause side effects including nausea, vomiting, diarrhoea, haemorrhoids and constipation, which can ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m.

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

From ‘Ozempic face’ to ‘Ozempic fingers’ and even ‘Wegovy butt,’ the potential side effects of weight loss medications have ...